Introduction to Stem Cell Therapy for Acute Toxic Hepatitis
Acute toxic hepatitis (ATH) is a severe liver disease characterized by rapid-onset inflammation and liver cell damage caused by exposure to hepatotoxic agents. Despite advances in medical care, the treatment options for ATH remain limited, and liver transplantation is often the only life-saving intervention. Thérapie par cellules souches has emerged as a promising therapeutic approach for ATH, offrant le potentiel de régénérer les tissus hépatiques endommagés et de restaurer la fonction hépatique.
Pathogenesis of Acute Toxic Hepatitis and Role of Stem Cells
ATH is triggered by various hepatotoxins, including drugs, toxins, et les polluants environnementaux. These agents induce oxidative stress, dysfonctionnement mitochondrial, and apoptosis in hepatocytes, leading to liver inflammation and necrosis. Cellules souches, cellules souches mésenchymateuses en particulier (MSC) et cellules souches hépatiques (HSC), have shown promise in mitigating these pathological processes. MSCs possess anti-inflammatory and immunomodulatory properties that can suppress liver inflammation and promote tissue repair. HSC, d'autre part, have the capacity to differentiate into functional hepatocytes, potentially replacing damaged liver cells and restoring liver function.
Preclinical Animal Studies of Stem Cell Therapy for Hepatitis
Preclinical studies in animal models of ATH have demonstrated the efficacy of thérapie par cellules souches. In animal models of acetaminophen-induced liver injury, administration of MSCs has been shown to reduce liver inflammation, promote hepatocyte regeneration, et améliorer la fonction hépatique. De la même manière, studies using HSCs have shown promising results, with transplanted HSCs successfully differentiating into functional hepatocytes and restoring liver function. These preclinical findings provide a strong rationale for further investigation of thérapie par cellules souches in the treatment of ATH.
